Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Researchers at the University of California, San Francisco, have figured out how a mutation in a protein, the TERT promoter, can grant tumor cells the ability to multiply with abandon. In a paper in Cancer Cell (2018, DOI: 10.1016/j.ccell.2018.08.003), UCSF’s Joseph F. Costello identifies the GABP-β1L subunit of the protein as a potentially important new cancer drug target. Telo Therapeutics, a start-up founded by Costello and his former graduate student Robert Bell, is working with GlaxoSmithKline to screen small-molecule libraries for inhibitors of the subunit.
This article has been sent to the following recipient: